Marker Therapeutics (NASDAQ:MRKR) vs. Monte Rosa Therapeutics (NASDAQ:GLUE) Critical Analysis

Marker Therapeutics (NASDAQ:MRKR – Get Free Report) and Monte Rosa Therapeutics (NASDAQ:GLUE – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, dividends, institutional ownership, profitability and analyst recommendations.

Profitability

This table compares Marker Therapeutics and Monte Rosa Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Marker Therapeutics N/A -60.00% -50.22%
Monte Rosa Therapeutics -186.24% -30.14% -20.35%

Earnings and Valuation

This table compares Marker Therapeutics and Monte Rosa Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Marker Therapeutics $3.55 million 3.93 -$12.16 million ($0.41) -2.04
Monte Rosa Therapeutics $123.67 million 6.27 -$38.63 million ($1.40) -6.48

Marker Therapeutics has higher earnings, but lower revenue than Monte Rosa Therapeutics. Monte Rosa Therapeutics is trading at a lower price-to-earnings ratio than Marker Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Marker Therapeutics has a beta of 1.65, indicating that its share price is 65% more volatile than the S&P 500. Comparatively, Monte Rosa Therapeutics has a beta of 1.4, indicating that its share price is 40% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and target prices for Marker Therapeutics and Monte Rosa Therapeutics, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Marker Therapeutics 1 1 2 0 2.25
Monte Rosa Therapeutics 1 2 8 1 2.75

Marker Therapeutics presently has a consensus price target of $10.00, indicating a potential upside of 1,095.31%. Monte Rosa Therapeutics has a consensus price target of $26.44, indicating a potential upside of 191.56%. Given Marker Therapeutics’ higher probable upside, equities analysts plainly believe Marker Therapeutics is more favorable than Monte Rosa Therapeutics.

Institutional & Insider Ownership

22.4% of Marker Therapeutics shares are owned by institutional investors. Comparatively, 80.0% of Monte Rosa Therapeutics shares are owned by institutional investors. 5.7% of Marker Therapeutics shares are owned by insiders. Comparatively, 6.4% of Monte Rosa Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Monte Rosa Therapeutics beats Marker Therapeutics on 9 of the 15 factors compared between the two stocks.

About Marker Therapeutics

(Get Free Report)

Marker Therapeutics is a clinical-stage biotechnology company focused on developing T-cell therapies for cancer. Its platform aims to produce T cells that recognize multiple tumor-associated antigens, with the goal of helping them target cancer cells while reducing the risk that tumors evade treatment by losing a single antigen. The company’s pipeline includes multi-antigen-specific T-cell candidates for blood cancers. Its programs have included MT-601, studied for lymphoma, and MT-401, developed for acute myeloid leukemia and other hematologic malignancies.

About Monte Rosa Therapeutics

(Get Free Report)

Monte Rosa Therapeutics is a clinical-stage biotechnology company developing molecular glue degraders, medicines designed to direct disease-associated proteins for disposal by the cell. Its discovery platform combines computational and experimental methods to identify and develop these potential treatments. The company’s research has included programs for cancer and immune-mediated diseases. Its pipeline includes MRT-6160, a VAV1 degrader being developed for autoimmune and inflammatory conditions, and MRT-8102, an investigational degrader targeting the NLRP3 inflammasome pathway.

Receive News & Ratings for Marker Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marker Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.